FoundationOne CDx
Foundation Medicine, Inc. · Decision date Nov 30, 2017
What did the FDA approve?
FDA records P170019 as an original PMA application. The recorded decision is approval, dated Nov 30, 2017.
FDA approval order statement
Approval for the FoundationOne CDx (F1CDx). This device is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. The F1CDx assay is a single-site assay performed at Foundation Medicine, Inc.Table 1: Companion diagnostic indicationsIndication: Non-small cell lung cancer (NSCLC). - Biomarker: EGFR exon 19 deletions and EGFR exon 21 L858R alterations. Therapy: Gilotrif (afatinib), Iressa (gefitinib), or Tarceva (erlotinib). - Biomarker: EGFR exon 20 T790M alterations. Therapy: Tagrisso (osimertinib). - Biomarker: ALK rearrangements. Therapy: Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib). - Biomarker: BRAF V600E. Therapy: Tafinlar (dabrafenib) in combination with Mekinist (trametinib).Indication: Melanoma. - Biomarker: BRAF V600E. Therapy: Tafinlar (dabrafenib) or Zelboraf (vemurafenib) - Biomarker: BRAF V600E and V600K. Therapy: Mekinist (trametinib) or Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib).Indication: Breast cancer. Biomarker: ERBB2 (HER2) amplification. Therapy: Herceptin (trastuzumab), Kadcyla (ado-trastuzumab-emtansine), orPerjeta (pertuzumab).Indication: Colorectal cancer. - Biomarker: KRAS wild-type (absence of mutations in codons 12 and 13). Therapy: Erbitux (cetuximab) - Biomarker: KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4). Therapy: Vectibix (panitumumab)Indication: Ovarian cancer. Biomarker: BRCA1/2 alterations. Therapy: Rubraca (rucaparib)
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Nov 30, 2017
Regulatory record facts
- Identifier
- P170019
- Regulatory pathway
- Premarket approval application
- Applicant
- Foundation Medicine, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Nov 30, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Foundation Medicine, Inc.
- Product code
- PQP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170019 received
Application receipt date recorded by FDA.
P170019 · FDA decision
APPR
P170019/S069 · Related supplement
FoundationOne CDx
Timeline entries are records held by MedtechLedger for P170019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Foundation Medicine, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 400 Summer St., Boston, MA, 02210
Sources and methodology
- Original FDA record: P170019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



